Intravenous pantoprazole: A new tool for acutely ill patients who require acid suppression

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. D, 2000, Pages

  Trépanier, Eric F ^a  

^a Global Health Consulting Inc   (Canada)

Author keywords

Intravenous; Pantoprazole; Parenteral therapy; Proton pump inhibitor

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PANTOPRAZOLE; SULFOXIDE;

GASTROINTESTINAL HEMORRHAGE; HUMAN; REFLUX ESOPHAGITIS; REVIEW; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BENZIMIDAZOLES; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; GASTROINTESTINAL HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; OMEPRAZOLE; SULFOXIDES; ZOLLINGER-ELLISON SYNDROME;

EID: 0034329897     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/608413     Document Type: Article

References (45)

1. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.
2. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997;11(Suppl B):66-73.
3. Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):15-25.
4. Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996;18:2-34.
5. Kromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 1995;56:443-54.
6. Shin JM, Besancon M, Prinz C, Simon A, Sachs G. Continuing development of acid pump inhibitors: site of action of pantoprazole. Aliment Pharmacol Ther 1994;8(Suppl 1):11-23.
7. Beil W, Staar U, Sewing KF. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol 1992;218:265-71.
8. Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996;8(Suppl 1):15-20.
9. Shin JM, Besancon M, Simon A, Sachs G. The site of action of pantoprazole in the gastric H+/K(+)-ATPase. Biochim Biophys Acta 1993;1148:223-33.
10. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995;9:363-78.
11. Simon B, Muller P, Bliesath H, et al. Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022 - inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990;4:239-45.
12. Straathof JWA, Gielkens HAJ, Wurst W, et al. Pentagastrin enhances the effect of intravenous pantoprazole. Gastroenterology 1997;112:A299. (Abst)
13. Pisegna JR, Martin P, McKeand W, Ohning G, Walsh JH, Paul J. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. Am J Gastroenterol 1999;94:2874-80.
14. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994;8(Suppl 1):39-46.
15. Hartmann M, Ehrlich A, Fuder H, et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998;12:1027-32.
16. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000;95:626-33.
17. Freston J, Taubel J, Lukasik N, Pan WJ, Chiu YL. NO lansoprazole or IV pantoprazole: which provides better pH control? Gastroenterology 2000;118(Suppl 2):3611. (Abst)
18. Barclay ML, Begg EJ, Robson RA, Peters WA, Ketelbey JW. Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. Aliment Pharmacol Ther 1999;13:1215-9.
19. Brunner G, Luna P, Hartmann M, Wurst W. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med 1996;69:225-31.
20. van Rensburg CJ, Thorpe A, Warren B, et al. Intragastric pH during pantoprazole infusion of 6mg/hour in patients with bleeding peptic ulceration. Gastroenterology 1999;116:A344. (Abst)
21. van Rensburg CJ, Thorpe A, Warren B, et al. Intragastric pH in patients with bleeding peptic ulceration during pantoprazole infusion of 8 mg/hour. Gastroenterology 1997;112:A321. (Abst)
22. Pue MA, Laroche J, Meineke I, De Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993;44:575-8.
23. Hartmann M, Bliesath H, Huber R, Koch HJ, Steinijans VW, Wurst W. Lack of influence of antacids on the pharmacokinetics of the new gastric H+/K+-ATPase inhibitor pantoprazole. Gastroenterology 1994;106:A91. (Abst)
24. Zech K, Steinijans VW, Huber R, Kolassa N, Radtke HW. Pharmacokinetics and drug interactions - relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996;34(1 Suppl):3-6.
25. Benet LZ, Zech K. Pharmacokinetics -a relevant factor for the choice of a drug? Aliment Pharmacol Ther 1994;8(Suppl 1):25-32.
26. Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 1994;32:385-99.
27. Simon B, Muller P, Hartmann M, et al. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 1990;28:443-7.
28. Tanaka M, Yamazaki H, Ryokawa Y, Hakusui H, Nakamichi N, Sekino H. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. Int J Clin Pharmacol Ther 1996;34:415-9.
29. Bliesath H, Huber R, Hartmann M, Luhmann R, Wurst W. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 1994;32:44-50.
30. Huber R, Hartmann M, Bliesath H, Luhmann R, Steinijans VW, Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34:185-94.
31. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994;8(Suppl 1):33-8.
32. Simon WA. Pantoprazole - Which cytochrome P450 isozymes are involved in its biotransformation? Gut 1995;37(Suppl 2):A135. (Abst)
33. Simon WA. Different metabolism of the proton pump inhibitors in man. Gastroenterology 1996;110:A258. (Abst)
34. Lins RL, De Clercq I, Hartmann M, et al. Pharmacokinetics of the proton pump inhibitor pantoprazole in patients with severe renal impairment. Gastroenterology 1994;106:A126. (Abst)
35. Kliem V, Bahlmann J, Hartmann M, Huber R, Luhmann R, Wurst W. Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Nephrol Dial Transplant 1998;13:1189-93.
36. Brunner G, Chang J, Hartmann M, Huber R, Bliesath H, Luhmann R, Pharmakokinetik von Pantoprazol bei Patienten mit Leberzirrhose. Med Klin 1994;89(Suppl I):189.
37. Breuel HP, Horak J, Horejsova M, et al. Pantoprazole in patients with varying degree of liver impairment in comparison to healthy controls. Gastroenterology 1998;114:A6. (Abst)
38. Breuel HP, Hartmann M, Bondy S, et al. Pantoprazole in the elderly: no dose-adjustment. Gut 1994;35(Suppl 4):77. (Abst)
39. Teyssen S, Singer MV, Heinze H, et al. Pantoprazole does not influence the pharmacokinetics of ethanol in healthy volunteers. Gastroenterology 1996;110(4 Suppl):A277. (Abst)
40. De Mey C, Meineke I, Steinijans VW, et al. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 1994;32:98-106.
41. Gugler R, Hartmann M, Rudi J, et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 1996;42:249-52.
42. Bliesath H, Huber R, Steinijans VW, Koch HJ, Wurst W, Mascher H. Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 1996;34:152-6.
43. Huber R, Bliesath H, Hartmann M, et al. Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 1998;36:521-4.
44. Schulz HU, Hartmann M, Krupp S, et al. Pantoprazole lacks interaction with the NSAID naproxen. Gastroenterology 2000;118(Suppl 2):A1304. (Abst)
45. Ferron GM, Paul JC, Fruncillo RJ, Martin PT, Yacoub L, Mayer PR. Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. J Clin Pharmacol 1999;39:945-50.